List of works - Karin Neukam

A model to predict the response to therapy against hepatitis C virus (HCV) including low-density lipoprotein receptor genotype in HIV/HCV-coinfected patients

scientific article published on 12 December 2012

A polymorphism linked to RRAS, SCAF1, IRF3 and BCL2L12 genes is associated with cirrhosis in hepatitis C virus carriers.

scientific article published on 16 October 2013

A review of current anti-HCV treatment regimens and possible future strategies

article

Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients with genotype 1 or 4.

scientific article published on 11 October 2011

Association of low-density lipoprotein receptor genotypes with hepatitis C viral load

scientific article published on 31 October 2013

Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV.

scientific article published on 14 October 2012

Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy

scientific article

Changes in liver steatosis evaluated by transient elastography with the controlled attenuation parameter in HIV-infected patients

scientific article

Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin

scientific article published on 22 July 2010

Changes in the response to treatment against chronic hepatitis C between 1999 and 2015: data from a prospective cohort

scientific article

Chronic hepatitis E in HIV patients: rapid progression to cirrhosis and response to oral ribavirin.

scientific article published on 10 April 2013

Combined use of aspartate aminotransferase, platelet count and matrix metalloproteinase 2 measurements to predict liver fibrosis in HIV/hepatitis C virus-coinfected patients

scientific article published in January 2011

Consumption of flavanol-rich cocoa acutely increases microcirculation in human skin

scientific article

Core amino acid variation at position 110 is associated with sustained virological response in Caucasian patients with chronic hepatitis C virus 1b infection

scientific article

Differences in virological response to peginterferon-α plus ribavirin in HIV-positive patients coinfected with HCV subtypes 1a or 1b.

scientific article published on June 2012

Different distributions of hepatitis C virus genotypes among HIV-infected patients with acute and chronic hepatitis C according to interleukin-28B genotype.

scientific article published on 6 March 2011

Dimension of chronic hepatitis C virus in HIV-infected patients in the interferon-free era: an overview from south Spain

scientific article

Effects of the genetic pattern defined by low-density lipoprotein receptor and IL28B genotypes on the outcome of hepatitis C virus infection.

scientific article published on 29 May 2013

Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia.

scientific article

Efficacy of chronic hepatitis C therapy with pegylated interferon and ribavirin in patients on methadone maintenance treatment

scientific article published on 6 October 2011

HAART and the liver: friend or foe?

scientific article published on March 2010

HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study.

scientific article published on May 2017

HIV-coinfection leads to a modest increase in plasma HCV-RNA load in patients with chronic HCV infection

scientific article published on 29 June 2012

Hepatic Safety of Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate Fixed-Dose Single-Tablet Regimen in HIV-Infected Patients with Active Hepatitis C Virus Infection: The hEPAtic Study

scientific article

Hepatic safety of RPV/FTC/TDF single tablet regimen in HIV/HCV-coinfected patients. Preliminary results of the hEPAtic Study

scientific article

Hepatic safety of efavirenz in HIV/hepatitis C virus-coinfected patients with advanced liver fibrosis.

scientific article published on 25 November 2011

Hepatitis C virus genotype 4 in Southern and Central Spain does not originate from recent foreign migration waves

scientific article published on 16 July 2013

Hepatitis C virus reinfection after sustained virological response in HIV-infected patients with chronic hepatitis C.

scientific article published on 23 July 2015

Hepatitis aguda C en varones homosexuales infectados por VIH: ¿una segunda oleada de coinfección por VIH y VHC?

scientific article published on 27 November 2014

High-risk Human Papilloma Virus Testing Improves Diagnostic Performance to Predict Moderate- to High-grade Anal Intraepithelial Neoplasia in Human Immunodeficiency Virus-infected Men Who Have Sex With Men in Low-to-Absent Cytological Abnormalities

scientific article published on 01 November 2019

IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against Hepatitis C Virus genotype 1 or 4 in Caucasians

scientific article

Impact of HIV infection on sustained virological response to treatment against hepatitis C virus with pegylated interferon plus ribavirin

scientific article published on 9 July 2015

Impact of IL28B genotype on first-week response to telaprevir-based therapy in HIV-HCV coinfection

scientific article

Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV–hepatitis C virus-coinfected patients with prior nonresponse or relapse

scientific article published in May 2011

Impact of genetic polymorphisms associated with nonalcoholic fatty liver disease on HIV-infected individuals

scientific article published on September 2015

Impact of interferon-free regimens on the glomerular filtration rate during treatment of chronic hepatitis C in a real-life cohort.

scientific article published on 28 January 2018

Impact of observer experience on the reproducibility of transient elastometry in HIV/HCV co-infected patients.

scientific article published on July 2009

Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy.

scientific article published in June 2011

Influence of the Combination of Low-Density Lipoprotein Receptor and Interleukin 28B Genotypes on Lipid Plasma Levels in HIV/Hepatitis C-Coinfected Patients

article

Interobserver concordance in controlled attenuation parameter measurement, a novel tool for the assessment of hepatic steatosis on the basis of transient elastography

scientific article published on August 2013

Interobserver concordance in the assessment of liver fibrosis in HIV/HCV-coinfected patients using transient elastometry.

scientific article published in July 2010

LDLr genotype modifies the impact of IL28B on HCV viral kinetics after the first weeks of treatment with PEG-IFN/RBV in HIV/HCV patients.

scientific article published on May 2012

Latest pharmacotherapy options for treating hepatitis C in HIV-infected patients.

scientific article published on August 2014

Liver Toxicity of Current Antiretroviral Regimens in HIV-Infected Patients with Chronic Viral Hepatitis in a Real-Life Setting: The HEPAVIR SEG-HEP Cohort

scientific article published on 5 February 2016

Liver Toxicity of Initial Antiretroviral Drug Regimens Including Two Nucleoside Analogs Plus One Non-Nucleoside Analog or One Ritonavir-Boosted Protease Inhibitor in HIV/HCV-Coinfected Patients

article

Liver safety of two nucleoside analogs plus efavirenz, nevirapine or a ritonavir-boosted protease inhibitor in HIV/HCV-coinfected drug-naïve patients.

scientific article

Liver tolerance of raltegravir-containing antiretroviral therapy in HIV-infected patients with chronic hepatitis C

article

Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients

scientific article published on 7 September 2011

Low incidence of acute hepatitis C virus infection among Southern Spanish HIV-infected individuals

scientific article published on 3 February 2017

Low-density lipoprotein receptor genotyping enhances the predictive value of IL28B genotype in HIV/hepatitis C virus-coinfected patients.

scientific article published in July 2011

Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV.

scientific article published in November 2010

No evidence of firstly acquired acute hepatitis C virus infection outbreak among HIV-infected patients from Southern Spain: a multicentric retrospective study from 2000-2014

scientific article

Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response.

scientific article published on 28 March 2013

Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus.

scientific article published on October 2010

Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load

scientific article published on 13 December 2011

Prevalencia de los marcadores de infección de los virus de las hepatitis en pacientes portadores del VIH en el sur de España

article

Reassessment of genotype 1 hepatitis C virus subtype misclassification by LiPA 2.0: implications for direct-acting antiviral treatment

scientific article

Response to a reinforced hepatitis B vaccination scheme in HIV-infected patients under real-life conditions

scientific article published on 10 April 2019

Strategies for assignment of HIV-HCV genotype-1-coinfected patients to either dual-therapy or direct-acting antiviral agent-based triple-therapy

scientific article published on 17 December 2013

Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy.

scientific article published on 22 November 2013

Sustained virological response in HIV/HCV co-infected patients without rapid virological response (RVR) on peginterferon-ribavirin therapy.

scientific article

Sustained virological response to pegylated interferon plus ribavirin leads to normalization of liver stiffness in hepatitis C virus-infected patients.

scientific article published on 28 February 2013

Tea flavanols inhibit cell growth and DNA topoisomerase II activity and induce endoreduplication in cultured Chinese hamster cells

scientific article

The impact of interleukin 28B rs12979860 single nucleotide polymorphism and liver fibrosis stage on response-guided therapy in HIV/HCV-coinfected patients.

scientific article published on November 2013

Twelve week post-treatment follow-up predicts sustained virological response to pegylated interferon and ribavirin therapy in HIV/hepatitis C virus co-infected patients.

scientific article published on 17 March 2011

Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infection.

scientific article published on November 2013

List of works by Karin Neukam

A model to predict the response to therapy against hepatitis C virus (HCV) including low-density lipoprotein receptor genotype in HIV/HCV-coinfected patients

A polymorphism linked to RRAS, SCAF1, IRF3 and BCL2L12 genes is associated with cirrhosis in hepatitis C virus carriers.

A review of current anti-HCV treatment regimens and possible future strategies

Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients with genotype 1 or 4.

Association of low-density lipoprotein receptor genotypes with hepatitis C viral load

Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV.

Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy

Changes in liver steatosis evaluated by transient elastography with the controlled attenuation parameter in HIV-infected patients

Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin

Changes in the response to treatment against chronic hepatitis C between 1999 and 2015: data from a prospective cohort

Chronic hepatitis E in HIV patients: rapid progression to cirrhosis and response to oral ribavirin.

Combined use of aspartate aminotransferase, platelet count and matrix metalloproteinase 2 measurements to predict liver fibrosis in HIV/hepatitis C virus-coinfected patients

Consumption of flavanol-rich cocoa acutely increases microcirculation in human skin

Core amino acid variation at position 110 is associated with sustained virological response in Caucasian patients with chronic hepatitis C virus 1b infection

Differences in virological response to peginterferon-α plus ribavirin in HIV-positive patients coinfected with HCV subtypes 1a or 1b.

Different distributions of hepatitis C virus genotypes among HIV-infected patients with acute and chronic hepatitis C according to interleukin-28B genotype.

Dimension of chronic hepatitis C virus in HIV-infected patients in the interferon-free era: an overview from south Spain

Effects of the genetic pattern defined by low-density lipoprotein receptor and IL28B genotypes on the outcome of hepatitis C virus infection.

Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia.

Efficacy of chronic hepatitis C therapy with pegylated interferon and ribavirin in patients on methadone maintenance treatment

HAART and the liver: friend or foe?

HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study.

HIV-coinfection leads to a modest increase in plasma HCV-RNA load in patients with chronic HCV infection

Hepatic Safety of Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate Fixed-Dose Single-Tablet Regimen in HIV-Infected Patients with Active Hepatitis C Virus Infection: The hEPAtic Study

Hepatic safety of RPV/FTC/TDF single tablet regimen in HIV/HCV-coinfected patients. Preliminary results of the hEPAtic Study

Hepatic safety of efavirenz in HIV/hepatitis C virus-coinfected patients with advanced liver fibrosis.

Hepatitis C virus genotype 4 in Southern and Central Spain does not originate from recent foreign migration waves

Hepatitis C virus reinfection after sustained virological response in HIV-infected patients with chronic hepatitis C.

Hepatitis aguda C en varones homosexuales infectados por VIH: ¿una segunda oleada de coinfección por VIH y VHC?

High-risk Human Papilloma Virus Testing Improves Diagnostic Performance to Predict Moderate- to High-grade Anal Intraepithelial Neoplasia in Human Immunodeficiency Virus-infected Men Who Have Sex With Men in Low-to-Absent Cytological Abnormalities

IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against Hepatitis C Virus genotype 1 or 4 in Caucasians

Impact of HIV infection on sustained virological response to treatment against hepatitis C virus with pegylated interferon plus ribavirin

Impact of IL28B genotype on first-week response to telaprevir-based therapy in HIV-HCV coinfection

Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV–hepatitis C virus-coinfected patients with prior nonresponse or relapse

Impact of genetic polymorphisms associated with nonalcoholic fatty liver disease on HIV-infected individuals

Impact of interferon-free regimens on the glomerular filtration rate during treatment of chronic hepatitis C in a real-life cohort.

Impact of observer experience on the reproducibility of transient elastometry in HIV/HCV co-infected patients.

Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy.

Influence of the Combination of Low-Density Lipoprotein Receptor and Interleukin 28B Genotypes on Lipid Plasma Levels in HIV/Hepatitis C-Coinfected Patients

Interobserver concordance in controlled attenuation parameter measurement, a novel tool for the assessment of hepatic steatosis on the basis of transient elastography

Interobserver concordance in the assessment of liver fibrosis in HIV/HCV-coinfected patients using transient elastometry.

LDLr genotype modifies the impact of IL28B on HCV viral kinetics after the first weeks of treatment with PEG-IFN/RBV in HIV/HCV patients.

Latest pharmacotherapy options for treating hepatitis C in HIV-infected patients.

Liver Toxicity of Current Antiretroviral Regimens in HIV-Infected Patients with Chronic Viral Hepatitis in a Real-Life Setting: The HEPAVIR SEG-HEP Cohort

Liver Toxicity of Initial Antiretroviral Drug Regimens Including Two Nucleoside Analogs Plus One Non-Nucleoside Analog or One Ritonavir-Boosted Protease Inhibitor in HIV/HCV-Coinfected Patients

Liver safety of two nucleoside analogs plus efavirenz, nevirapine or a ritonavir-boosted protease inhibitor in HIV/HCV-coinfected drug-naïve patients.

Liver tolerance of raltegravir-containing antiretroviral therapy in HIV-infected patients with chronic hepatitis C

Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients

Low incidence of acute hepatitis C virus infection among Southern Spanish HIV-infected individuals

Low-density lipoprotein receptor genotyping enhances the predictive value of IL28B genotype in HIV/hepatitis C virus-coinfected patients.

Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV.

No evidence of firstly acquired acute hepatitis C virus infection outbreak among HIV-infected patients from Southern Spain: a multicentric retrospective study from 2000-2014

Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response.

Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus.

Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load

Prevalencia de los marcadores de infección de los virus de las hepatitis en pacientes portadores del VIH en el sur de España

Reassessment of genotype 1 hepatitis C virus subtype misclassification by LiPA 2.0: implications for direct-acting antiviral treatment

Response to a reinforced hepatitis B vaccination scheme in HIV-infected patients under real-life conditions

Strategies for assignment of HIV-HCV genotype-1-coinfected patients to either dual-therapy or direct-acting antiviral agent-based triple-therapy

Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy.

Sustained virological response in HIV/HCV co-infected patients without rapid virological response (RVR) on peginterferon-ribavirin therapy.

Sustained virological response to pegylated interferon plus ribavirin leads to normalization of liver stiffness in hepatitis C virus-infected patients.

Tea flavanols inhibit cell growth and DNA topoisomerase II activity and induce endoreduplication in cultured Chinese hamster cells

The impact of interleukin 28B rs12979860 single nucleotide polymorphism and liver fibrosis stage on response-guided therapy in HIV/HCV-coinfected patients.

Twelve week post-treatment follow-up predicts sustained virological response to pegylated interferon and ribavirin therapy in HIV/hepatitis C virus co-infected patients.

Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infection.